NASDAQ:MDXG

MiMedx Group - MDXG Stock Forecast, Price & News

$2.84

+0.13 (+4.80%)

(As of 09/27/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.72
▼
$2.87
50-Day Range: $2.71
▼
$4.22
52-Week Range: $2.68
▼
$8.69

Volume: 494,808 shs
Average Volume: 636,542 shs
Market Capitalization: $322.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

MiMedx Group MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 181.7% Upside
$8.00 Price Target
Short Interest: Bearish
3.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.37
Based on 10 Articles This Week
Insider Trading: Selling Shares
$272,928 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.33) to ($0.17) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

254th out of 1,071 stocks

Surgical & Medical Instruments Industry

30th out of 106 stocks

3.5

Analyst's Opinion

Consensus Rating
MiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, MiMedx Group has a forecasted upside of 181.7% from its current price of $2.84.
Amount of Analyst Coverage
MiMedx Group has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.63% of the float of MiMedx Group has been sold short.
Short Interest Ratio / Days to Cover
MiMedx Group has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in MiMedx Group has recently increased by 4.71%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
MiMedx Group does not currently pay a dividend.
Dividend Growth
MiMedx Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDXG.

2.4

News and Social Media Coverage

News Sentiment
MiMedx Group has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for MiMedx Group this week, compared to 1 article on an average week.
Search Interest
10 people have searched for MDXG on MarketBeat in the last 30 days.
MarketBeat Follows
Only 3 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MiMedx Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $272,928.00 in company stock.
Percentage Held by Insiders
19.60% of the stock of MiMedx Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
60.86% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MiMedx Group are expected to grow in the coming year, from ($0.33) to ($0.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MiMedx Group is -11.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MiMedx Group is -11.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About MiMedx Group (NASDAQ:MDXG) Stock

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MDXG Stock News Headlines

September 27, 2022 | americanbankingnews.com

Zacks Small Cap Comments on MiMedx Group, Inc.'s Q4 2022 Earnings (NASDAQ:MDXG)

September 23, 2022 | finance.yahoo.com

MDXG: New Product Launches

September 22, 2022 | finance.yahoo.com

Institutions along with individual investors who hold considerable shares inMiMedx Group, Inc. (NASDAQ:MDXG) come under pressure; lose 14% of holdings value

September 20, 2022 | finance.yahoo.com

MIMEDX Announces Launch of AXIOFILL™

September 19, 2022 | finance.yahoo.com

MIMEDX Announces Launch of AMNIOEFFECT™

September 16, 2022 | nasdaq.com

MiMedx Group, Inc. (NASDAQ:MDXG) insiders sold US$1.7m worth of stock suggesting impending weakness.

September 12, 2022 | finance.yahoo.com

MIMEDX, public regenerative medicine company, joins the RegenMed Hub’s Innovation Accelerator in Winston-Salem

September 12, 2022 | finance.yahoo.com

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

September 12, 2022 | finance.yahoo.com

MDXG: New Captain on the Bridge

September 7, 2022 | marketwatch.com

MiMedx Group Ousts CEO Wright; Names Newton as Interim CEO >MDXG

August 26, 2022 | finance.yahoo.com

Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin

August 5, 2022 | uk.investing.com

MiMedx Group Misses Q2 EPS by 5c

August 4, 2022 | finance.yahoo.com

MIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference

August 4, 2022 | finance.yahoo.com

MDXG: 2Q:22 Financial and Operational Results

August 2, 2022 | finance.yahoo.com

MIMEDX Announces Second Quarter 2022 Operating and Financial Results

August 1, 2022 | nasdaq.com

Investors in MiMedx Group (NASDAQ:MDXG) have unfortunately lost 77% over the last five years

July 27, 2022 | finance.yahoo.com

MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

July 24, 2022 | finance.yahoo.com

Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?

July 20, 2022 | finance.yahoo.com

MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

July 18, 2022 | finance.yahoo.com

MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

June 15, 2022 | finance.yahoo.com

MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis

June 14, 2022 | finance.yahoo.com

Prescience Point Capital Management Says MiMedx Shareholders Have Spoken: Voiced Their Desire For Change

June 7, 2022 | finance.yahoo.com

MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting

June 3, 2022 | finance.yahoo.com

MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders

June 2, 2022 | finance.yahoo.com

MIMEDX Addresses Presentation by Prescience Point

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MDXG Company Calendar

Last Earnings: 8/02/2022
Today: 9/28/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MDXG
CUSIP: N/A
CIK: 1376339
Web: www.mimedx.com
Phone: (770) 651-9100
Fax: 678-384-6741
Employees: 811
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +181.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,280,000.00
Net Margins: -9.64%
Pretax Margin: -8.26%
Return on Equity: N/A
Return on Assets: -13.89%

Debt

Debt-to-Equity Ratio: 586.91
Current Ratio: 3.53
Quick Ratio: 3.17

Sales & Book Value

Annual Sales: $258.61 million
Price / Sales: 1.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 113,610,000
Free Float: 91,342,000
Market Cap: $322.65 million
Optionable: Optionable
Beta: 1.75

Key Executives

Mr. K. Todd Newton (Age 59)
Interim CEO & Director
Comp: $69.5k

Mr. Peter Martin Carlson CPA (Age 58)
Chief Financial Officer
Comp: $787.81k

Mr. William F. Hulse IV (Age 48)
Gen. Counsel & Chief Admin. Officer
Comp: $733.69k

Dr. Rohit Kashyap Ph.D. (Age 51)
Pres of Wound Care & Surgical
Comp: $741.29k

Dr. Robert Benjamin Stein M.D. (Age 71)
Ph.D., Pres of Regenerative Medicine & Biologics Innovation
Comp: $731.25k

Mr. Scott M. Turner (Age 57)
Sr. VP of Operations & Procurement

Mr. William L. Phelan
Sr. VP & Chief Accounting Officer

Mr. John J. Howarth
Sr. VP of Investor Relations

Mr. Mark P. Graves (Age 56)
Sr. VP & Chief Compliance Officer

Hilary Dixon
VP of Investor Relations & Corp. Strategic Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDXG Stock - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings or view top-rated stocks.
What is MiMedx Group's stock price forecast for 2022?: 1 Wall Street research analysts have issued 1 year target prices for MiMedx Group's stock. Their MDXG share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 181.7% from the stock's current price.
View analysts price targets for MDXG or view top-rated stocks among Wall Street analysts.
How have MDXG shares performed in 2022?: MiMedx Group's stock was trading at $6.04 at the beginning of 2022. Since then, MDXG stock has decreased by 53.0% and is now trading at $2.84.
View the best growth stocks for 2022 here.
When is MiMedx Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our MDXG earnings forecast.
How were MiMedx Group's earnings last quarter?: MiMedx Group, Inc. (NASDAQ:MDXG) issued its earnings results on Tuesday, August, 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.05. The company earned $66.88 million during the quarter, compared to analyst estimates of $65.07 million.

What is MiMedx Group's stock symbol?: MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
Who are MiMedx Group's major shareholders?: MiMedx Group's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (3.54%), Federated Hermes Inc. (2.31%), Richmond Brothers Inc. (2.24%), Northern Trust Corp (0.85%), Parsons Capital Management Inc. RI (0.57%) and Renaissance Technologies LLC (0.56%). Insiders that own company stock include Mark Graves, Peter M Carlson, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends.
How do I buy shares of MiMedx Group?: Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MiMedx Group's stock price today?: One share of MDXG stock can currently be purchased for approximately $2.84.
How much money does MiMedx Group make?: MiMedx Group (NASDAQ:MDXG) has a market capitalization of $322.65 million and generates $258.61 million in revenue each year. The company earns $-10,280,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.
How many employees does MiMedx Group have?: The company employs 811 workers across the globe.
How can I contact MiMedx Group?: MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The official website for the company is www.mimedx.com. The company can be reached via phone at (770) 651-9100, via email at investorrelations@mimedx.com, or via fax at 678-384-6741.

This page (NASDAQ:MDXG) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MiMedx Group - MDXG Stock Forecast, Price & News

MiMedx Group MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MiMedx Group (NASDAQ:MDXG) Stock

MDXG Stock News Headlines

MDXG Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MDXG Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™